Condition: Ulcerative Colitis Chronic Mild · Ulcerative Colitis Chronic Moderate · Ulcerative Colitis Chronic · Sponsor: Rise Therapeutics LLC
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
This description comes directly from the study's public registry record.
Janet Stephens, PhD · 6504178556 · jstephens@risetherapeutics.com
Christian Freguia, PhD · 2159231818 · cfreguia@risetherapeutics.com
Always discuss trial participation with your own doctor first.
| Amicis Research Center | Valencia, California, United States | Recruiting |
| AP Medical Research LLC | Miami, Florida, United States | Recruiting |
| Edward Jenner Research Group, LLC | Plantation, Florida, United States | Recruiting |
| Adtremed Research Clinic | Tampa, Florida, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05666960